Skip to main content
  • SUGAR Trial Hits Sour Note: Potential Superiority of Cre8 EVO DES vs. Resolute Onyx DES at 1 Year Disappears at 2 Years

    BOSTON — Despite a signal of potential superiority of the Cre8 EVO drug-eluting stent (DES) over the Resolute Onyx DES at 1 year post-percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM), the 2-year results failed to show superiority of the new DES.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details